Elsevier S & T

Advances in Antiviral Drug Design

De Clercq, E.

In stock
No reviews
55.500 KD inc. VAT
License
Table of contents
  • Cover
  • Contentsv
  • List of Contributorsvii
  • Prefaceix
  • Chapter 1. Status Presens of Antiviral Drugs And Strategies: Part I: DNA Viruses and Retroviruses1
  • Abstract1
  • I. Introduction1
  • II. Parvoviruses2
  • III. Polyomaviruses2
  • IV. Papillomaviruses3
  • V. Adenoviruses4
  • VI. alpha-Herpesviruses (HSV-1, HSV-2, VZV)4
  • VII. beta-Herpesviruses (CMV, HHV-6, HHV-7)6
  • VIII. gamma-Herpesviruses (EBV, HHV-8)8
  • IX. Poxviruses (variola, vaccinia, monkeypox, molluscum contagiosum, orf ƒ)9
  • X. Hepadnaviruses (HBV)11
  • XI. Retroviruses (HIV)14
  • XII. Conclusion40
  • Acknowledgements46
  • References46
  • Chapter 2. Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUS59
  • Abstract59
  • I. Introduction59
  • II. Picornaviruses (entero- and rhinoviruses)60
  • III. Alpha- and flaviviruses (yellow fever, dengue, west nile, ƒ)62
  • IV. Hepaciviruses (HCV)63
  • V. Coronaviruses (SARS)70
  • VI. Orthomyxoviruses (influenza A, B)73
  • VII. Paramyxoviruses (parainfluenza, measles, mumps, RSV, hMPV, Nipah, ƒ)75
  • VIII. Arena-, bunya-, rhabdo- and filoviruses83
  • IX. Reoviruses96
  • X. Conclusion97
  • References97
  • Chapter 3. Methylenecyclopropane Analogues of Nucleosides as Anti-herpes Agents113
  • Abstract113
  • I. Introduction113
  • II. Design116
  • III. Synthesis119
  • IV. Antiviral activity134
  • Acknowledgements159
  • References160
  • Chapter 4. Synthesis and antiviral evaluation of broad spectrum, orally active analogs of cidofovir167
  • I. Introduction167
  • II. Synthesis of hexadecyloxypropyl and related esters of cidofovir168
  • III. Antiviral evaluation and spectrum of activity171
  • IV. Structure activity relationships173
  • V. Cellular metabolism175
  • VI. Oral pharmacokinetics and tissue distribution176
  • VII. Antiviral activity in animal models of viral diseases178
  • VIII. Alkoxyalkyl esters of (S)-HPMPA and other acyclic nucleoside phosphonates181
  • IX. Conclusions182
  • Acknowledgements182
  • References183
  • Chapter 5. CCR5 antagonistsCCR5 antagonists for the treatment ofHIV infection and AIDS185
  • I. Introduction185
  • II. Inhibition of HIV entry186
  • III. CCR5 as a drug target188
  • IV. The discovery of novel CCR5 antagonists190
  • V. Molecular mechanisms199
  • VI. Resistance to CCR5 antagonists in vitro and in the clinic201
  • VII. Conclusions202
  • References204
  • Chapter 6. The medicinal chemistry of the DATADATA and DAPYDAPY series of HIV-1HIV-1 non-nucleoside213
  • Abstract213
  • I. Introduction214
  • II. The diaryltriazine (DATA) series216
  • III. The diarylpyrimidine (DAPY) series222
  • IV. Conclusion239
  • Acknowledgements239
  • References239
  • Index243
Book details
  • Vendor Elsevier S & T
  • SKU 9780444521736
  • ISBN-13 9780080548241
  • Author De Clercq, E.
  • Category Medical
  • Subject Pharmacology

Do you have questions about this book?

Ask an expert!

Description eBook delivery & access Reviews
Regularly reviewing the "state-of-the-art" developments in the antiviral drug research field, this latest volume spans the conceptual design and chemical synthesis of new antiviral compounds. It discusses their structure-activity relationship, mechanism and targets of action, pharmacological behavior, antiviral activity spectrum, and therapeutic potential for clinical use.